Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapeutics to address serious viral infections. Its primary product candidate, bemnifosbuvir, a nucleotide NS5B inhibitor, targets COVID-19 caused by SARS-CoV-2 and its variants. The company is also advancing bemnifosbuvir in combination with ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment, with this regimen currently in Phase 3 clinical trials. Additionally, Atea Pharmaceuticals develops AT-587 for chronic hepatitis E virus infection, which is in Phase 1 trials. Operating within the biotechnology sector of healthcare, the company holds a license agreement with MSD International GmbH for ruzasvir's development, manufacture, and commercialization. Founded in 2012 and headquartered in Boston, Massachusetts, Atea Pharmaceuticals plays a key role in advancing innovative oral therapies for viral diseases affecting global patient populations.